Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3
| PHPIX Fund | USD 27.85 0.48 1.75% |
Slightly above 54% of Pharmaceuticals Ultrasector's investors are presently thinking to get in. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that some investors are interested at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
Filed transaction by Eli Lilly and Officer: Interim Cfo, Group Vp. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at benzinga.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in price to sales among similar funds. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| LGPSX | Profunds Large | 0.87 | ||||
| LGPIX | Large Cap | 0.85 | ||||
| UIPSX | Ultrashort Mid-cap | 0.71 | ||||
| UIPIX | Ultrashort Mid-cap | 0.69 | ||||
| BRPIX | Bear Profund | 0.44 | ||||
| BRPSX | Bear Profund | 0.39 | ||||
| SRPSX | Short Real | 0.61 | ||||
| SRPIX | Short Real | 0.65 | ||||
| TEPIX | Technology Ultrasector | 2.08 | ||||
| TEPSX | Technology Ultrasector | 2.08 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |